ᱚᱠᱥᱯᱷᱳᱨᱰ-ᱮᱥᱴᱨᱟᱡᱮᱱᱮᱠᱟ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ

ᱚᱠᱥᱯᱷᱳᱨᱰ-ᱮᱥᱴᱨᱟᱡᱮᱱᱮᱠᱟ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ
	A vial of COVID-19 Vaccine AstraZeneca
ᱴᱤᱠᱟᱹ ᱨᱮᱭᱟᱜ ᱵᱚᱨᱱᱚᱱ
ᱡᱚᱥ ᱟᱡᱟᱨ	SARS-CoV-2
ᱞᱮᱠᱟᱱ	viral
ᱠᱞᱤᱱᱤᱠᱟᱞ ᱰᱮᱴᱟ
ᱵᱮᱯᱟᱨ ᱧᱩᱛᱩᱢᱠᱚ	Vaxzevria, Covishield
ᱮᱴᱟᱜ ᱧᱩᱛᱩᱢ	AZD1222,; ChAdOx1 nCoV-19,; ChAdOx1-S,; COVID-19 Vaccine AstraZeneca,; AstraZeneca COVID-19 Vaccine,; AZD2816
ᱰᱮᱴᱟ	EU EMA: yes; US DailyMed: AstraZeneca_COVID-19_Vaccine;
ᱦᱚᱲᱢᱚᱜ; ᱛᱷᱚᱠ	AU: B2 ; ;
ᱵᱮᱵᱷᱟᱨ ᱨᱮᱱᱟᱜ; ᱴᱷᱟᱶ	Intramuscular
ᱮ.ᱴᱤ.ᱥᱤ ᱠᱳᱰ	None;
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ	AU: S4 (Prescription only) ; CA: Schedule D; Authorized by interim order ; UK: Conditional and temporary authorisation to supply ; EU: Conditional marketing authorisation ; KR, BR – Approved; Full list : List of Oxford–AstraZeneca COVID-19 vaccine authorizations
ᱩᱯᱨᱩᱢᱤᱭᱟᱹ
ᱥᱤ.ᱮ.ᱮᱥ ᱱᱚᱢᱵᱚᱨ	2420395-83-9;
ᱰᱨᱟᱜᱵᱮᱸᱠ	DB15656;
ᱭᱩ.ᱮᱱ.ᱟᱭ.ᱟᱭ	B5S3K2V0G8;
ᱠᱮ.ᱤ.ᱡᱤ.ᱡᱤ	D12115;

ᱚᱠᱥᱯᱷᱳᱨᱰ-ᱮᱥᱴᱨᱟᱡᱮᱱᱮᱠᱟ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ ᱫᱚ ᱚᱠᱥᱯᱷᱳᱨᱰ ᱡᱮᱜᱮᱛ ᱵᱤᱨᱫᱟᱹᱜᱟᱲ ᱟᱨ ᱮᱥᱴᱨᱟᱡᱮᱱᱮᱠᱟ ᱟᱜ ᱵᱮᱱᱟᱣᱟᱜ ᱢᱤᱫᱴᱮᱱ ᱴᱤᱠᱟᱹ ᱠᱟᱱᱟ᱾ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱫᱚ ᱵᱷᱮᱠᱴᱚᱨ ᱦᱤᱥᱟᱹᱵᱛᱮ ᱥᱤᱢᱯᱟᱱᱡᱤ ᱟᱜ ᱮᱰᱱᱳᱵᱷᱟᱭᱨᱟᱥ ᱵᱮᱵᱷᱟᱨᱚᱜᱼᱟ᱾ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱫᱚ ᱵᱟᱨᱮᱭᱟ ᱰᱳᱡᱽ ᱮᱢ ᱦᱩᱭᱩᱜᱼᱟ᱾ ᱯᱟᱹᱦᱤᱞ ᱰᱳᱡᱽ ᱮᱢ ᱛᱟᱭᱚᱢ ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮ ᱫᱚᱥᱟᱨ ᱰᱳᱡᱽ ᱮᱢ ᱦᱩᱭᱩᱜᱼᱟ᱾

ᱚᱠᱥᱯᱷᱳᱨᱰ ᱡᱮᱜᱮᱛ ᱵᱤᱨᱫᱟᱹᱜᱟᱲ ᱨᱮᱱᱟᱜ ᱡᱮᱱᱟᱨ ᱤᱱᱥᱴᱤᱴᱤᱣᱴ ᱟᱨ ᱚᱠᱥᱯᱷᱳᱨᱰ ᱵᱷᱮᱠᱥᱤᱱ ᱜᱽᱨᱩᱯ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱵᱮᱱᱟᱣ ᱨᱮᱱᱟᱜ ᱠᱳ ᱠᱷᱚᱸᱫᱨᱚᱝ ᱞᱮᱫᱟ᱾ ᱱᱚᱣᱟ ᱠᱷᱚᱸᱫᱨᱚᱝ ᱨᱮ ᱥᱟᱨᱟ ᱜᱤᱞᱵᱟᱨᱴ, ᱮᱰᱨᱤᱭᱟᱱ ᱦᱤᱞ, ᱮᱱᱰᱨᱩ ᱯᱳᱞᱟᱨᱰ, ᱴᱮᱨᱮᱥᱟ ᱞᱮᱢᱵᱮ, ᱥᱮᱱᱰᱤ ᱰᱚᱜᱽᱞᱟᱥ, ᱠᱮᱛᱷᱨᱤᱱ ᱜᱨᱤᱱ ᱢᱮᱱᱟᱭᱟ᱾ ᱒᱐᱒᱐ ᱥᱮᱨᱢᱟ ᱨᱮᱱᱟᱜ ᱰᱤᱥᱮᱢᱵᱚᱨ ᱪᱟᱸᱫᱚ ᱫᱷᱟᱹᱵᱤᱡ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱛᱮᱥᱟᱨ ᱫᱷᱟᱣ ᱨᱮᱱᱟᱜ ᱠᱷᱚᱸᱫᱨᱚᱝ ᱦᱩᱭᱞᱮᱱᱟ᱾

ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱫᱚ ᱒᱐᱒᱐ ᱥᱮᱨᱢᱟ ᱨᱮᱱᱟᱜ ᱓᱐ ᱰᱤᱥᱮᱢᱵᱚᱨ ᱡᱩᱠᱛᱚ ᱨᱟᱡᱡᱚ ᱨᱮ ᱵᱮᱵᱷᱟᱨ ᱨᱮᱱᱟᱜ ᱟᱹᱭᱫᱟᱹᱨᱤᱭ ᱧᱟᱢ ᱟᱠᱟᱫᱟ ᱟᱨ ᱔ ᱡᱟᱱᱩᱣᱟᱨᱤ ᱒᱐᱒᱑ ᱠᱷᱚᱱ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱮᱢ ᱮᱛᱦᱚᱵ ᱟᱠᱟᱱᱟ᱾

ᱯᱷᱮᱰᱟᱛ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱵᱟᱦᱨᱮ ᱡᱚᱱᱚᱲ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱥᱟ.ᱠᱷᱭᱟ.ᱛ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

↑ ^᱑.᱐ ^᱑.᱑ ^᱑.᱒ "COVID-19 Vaccine AstraZeneca PI". Therapeutic Goods Administration (TGA).
↑ ^᱒.᱐ ^᱒.᱑ "COVID-19 Vaccine AstraZeneca". Therapeutic Goods Administration (TGA). 16 February 2021. Archived from the original on 18 March 2021. Retrieved 16 February 2021.
↑ ^᱓.᱐ ^᱓.᱑ "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA). Archived from the original on 21 April 2021. Retrieved 27 March 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA About
↑ "Already produced 40–50 million dosages of Covishield vaccine, says Serum Institute". The Hindu. 28 December 2020. Archived from the original on 20 April 2021. Retrieved 30 December 2020.
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named AstraZeneca_PR
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named AZ CDC ACIP
↑ "AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine". AstraZeneca (Press release). 30 April 2020. Archived from the original on 16 November 2020. Retrieved 13 January 2021.
↑ ^᱙.᱐ ^᱙.᱑ "Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 9 March 2021. Retrieved 4 January 2021.
↑ ^᱑᱐.᱐ ^᱑᱐.᱑ "Regulatory Decision Summary – AstraZeneca COVID-19 Vaccine". Health Canada. 26 February 2021. Archived from the original on 11 March 2021. Retrieved 26 February 2021.
↑ "First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated". Astrazeneca. 27 June 2021. Archived from the original on 27 June 2021. Retrieved 24 July 2021.
↑ "Summary for ARTG Entry: 349072 COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection multidose vial".^{[permanent dead link]}
↑ "AstraZeneca COVID-19 Vaccine monograph" (PDF). AstraZeneca. 26 February 2021. Archived (PDF) from the original on 30 March 2021. Retrieved 5 March 2021.
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named EMA recommendation
↑ "European Commission authorises third safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 10 February 2021. Retrieved 29 January 2021.
↑ "Conditions of Authorisation for COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 18 February 2021. Retrieved 4 January 2021.
↑ "아스트라제네카社 코로나19 백신 품목허가" [AstraZeneca's Corona 19 vaccine product license]. 식품의약품안전처 (in ᱠᱚᱨᱤᱭᱟᱹᱱ). 식품의약품안전처. 10 February 2021. Archived from the original on 10 February 2021. Retrieved 10 February 2021.
↑ "Anvisa aprova registro definitivo da vacina de Oxford no Brasil" [Anvisa approves definitive registration of Oxford vaccine in Brazil]. G1 (in ᱵᱨᱟᱡᱤᱞᱤᱭᱟᱱ ᱯᱩᱨᱛᱜᱟᱞᱤ). 12 March 2021. Archived from the original on 20 March 2021. Retrieved 20 March 2021.

[ChAdOx1-S_AU_PI-1] ᱑.᱐ ^᱑.᱑ ^᱑.᱒ "COVID-19 Vaccine AstraZeneca PI". Therapeutic Goods Administration (TGA).

[AU_TGA_decision-2] ᱒.᱐ ^᱒.᱑ "COVID-19 Vaccine AstraZeneca". Therapeutic Goods Administration (TGA). 16 February 2021. Archived from the original on 18 March 2021. Retrieved 16 February 2021.

[COVID-19_Vaccine_AstraZeneca_EPAR-3] ᱓.᱐ ^᱓.᱑ "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA). Archived from the original on 21 April 2021. Retrieved 27 March 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[CA_About-4] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA About

[Covishield-5] "Already produced 40–50 million dosages of Covishield vaccine, says Serum Institute". The Hindu. 28 December 2020. Archived from the original on 20 April 2021. Retrieved 30 December 2020.

[AstraZeneca_PR-6] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named AstraZeneca_PR

[AZ_CDC_ACIP-7] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named AZ CDC ACIP

[8] "AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine". AstraZeneca (Press release). 30 April 2020. Archived from the original on 16 November 2020. Retrieved 13 January 2021.

[UK_HC_info-9] ᱙.᱐ ^᱙.᱑ "Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 9 March 2021. Retrieved 4 January 2021.

[CA_authorization-10] ᱑᱐.᱐ ^᱑᱐.᱑ "Regulatory Decision Summary – AstraZeneca COVID-19 Vaccine". Health Canada. 26 February 2021. Archived from the original on 11 March 2021. Retrieved 26 February 2021.

[11] "First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated". Astrazeneca. 27 June 2021. Archived from the original on 27 June 2021. Retrieved 24 July 2021.

[12] "Summary for ARTG Entry: 349072 COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection multidose vial".^{[permanent dead link]}

[13] "AstraZeneca COVID-19 Vaccine monograph" (PDF). AstraZeneca. 26 February 2021. Archived (PDF) from the original on 30 March 2021. Retrieved 5 March 2021.

[EMA_recommendation-14] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named EMA recommendation

[EU_PR_20210129-15] "European Commission authorises third safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 10 February 2021. Retrieved 29 January 2021.

[UK_auth-16] "Conditions of Authorisation for COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 18 February 2021. Retrieved 4 January 2021.

[mfds2102-17] "아스트라제네카社 코로나19 백신 품목허가" [AstraZeneca's Corona 19 vaccine product license]. 식품의약품안전처 (in ᱠᱚᱨᱤᱭᱟᱹᱱ). 식품의약품안전처. 10 February 2021. Archived from the original on 10 February 2021. Retrieved 10 February 2021.

[18] "Anvisa aprova registro definitivo da vacina de Oxford no Brasil" [Anvisa approves definitive registration of Oxford vaccine in Brazil]. G1 (in ᱵᱨᱟᱡᱤᱞᱤᱭᱟᱱ ᱯᱩᱨᱛᱜᱟᱞᱤ). 12 March 2021. Archived from the original on 20 March 2021. Retrieved 20 March 2021.

[᱓]

[᱔]

[᱕]

[᱖]

[᱗]

[᱘]

[᱑]

[᱒]

[᱙]

[᱑᱐]

[᱑᱑]

[᱑᱒]

[᱑᱓]

[᱑᱖]

[᱑᱔]

[᱑᱕]

[᱑᱗]

[᱑᱘]